Spain, Feb. 27 -- The European Investment Bank (EIB) has signed a €20 million loan with Spain company Universal DX to support development and commercialization of cutting-edge blood-based liquid biopsy solutions for the early detection of cancer. The survival rate of certain cancers such as colorectal cancer, can increase significantly if detected at an early stage.The EIB financing will support the expansion of Universal Dx's most advanced product, Signal-C(R) for Colorectal Cancer Screening and the development of other pipeline products: Signal-Li and Signal-Lu for Liver and Lung cancer respectively. The loan will also support Universal DX international expansion plan, including advancing a large clinical trial in the US for FDA app...